期刊文献+

冻干重组人脑利钠肽治疗顽固性心衰伴肾功能不全患者疗效观察 被引量:6

Effect observation of lyophilized recombinant human brain natriuretic peptide for treatment of patients of refractory heart failure with renal inadequacy
下载PDF
导出
摘要 目的观察冻干重组人脑利钠肽治疗顽固性心衰伴肾功能不全患者疗效。方法选取2008年8月~2011年9月我院82例顽固性心衰伴肾功能的患者分为治疗组32例,对照组50例。对照组采用常规治疗,治疗组加用新活素,先给予负荷剂量1.500μg/kg静脉缓慢推注,然后0.01μg/(kg.min)静脉滴注。结果在心功能方面,治疗组较对照组改善更加明显,达到显著性水平(Z=2.1,P<0.05),对照组有效率为74.0%,而治疗组为87.5%;在肾功能、尿量、NT-proBNP和心脏超声方面,治疗组均较对照组改善更加明显,差异有统计学意义。结论冻干重组人脑利钠肽治疗顽固性心衰伴肾功能不全患者疗效显著,无明显不良反应。 Objective To observation the effect of rhBNP on renal inadequacy patients with refractory heart failure. Methods Selected 82 patients of refractory heart failure with renal inadequacy were randomly divided into treatment group of 32 patients and control group of 50 patients in our hospital from August 2008 to September 2011. Control group was given routine treatment while treatment group was received routine treatment plus rhBNP with an initial loading dose of 1.500 μg/kg and then a slow mainline dose of 0.01 μg/(kg.min). Results The treatment group was obviously improved in heart function when compared with the control group, re.aching the level of significance(Z = 2.1, P 〈 0.05),. The effective rate in the control group was 74.0% while that of the treatment group was 87.5%, and the treatment group was more obviously im- proved in renal function, Urine volume, NT-proBNP and echocardiography than those in control group, reaching the level of significance. Conclusion Effect of rhBNP for treatment on patients with refractory heart failure and renal inadequacy is evidently good without obviously adverse effect.
作者 罗金明
出处 《中国现代医生》 2012年第28期28-29,共2页 China Modern Doctor
关键词 RHBNP 心力衰竭 肾功能不全 RhBNP Heart failure Renal inadequacy
  • 相关文献

参考文献6

  • 1沈潞华.老年心力衰竭合并肾功能不全的临床处理[J].中国实用内科杂志,2007,27(9):652-653. 被引量:13
  • 2De Castro FD, Chaves PC,Leite-Moreira AF. Cardiorenal syndrome and its pathophysiological implications[J]. Rev port cardiol,2010,29(10):1535- 1554.
  • 3袁方,刘华,张敏,方唯一.重组人B型利钠肽静脉注射对急性失代偿性心力衰竭合并急性肾损伤患者心、肾功能的影响[J].上海医学,2011,34(12):938-941. 被引量:9
  • 4Zhang J,Fu X,Jua X,et al. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary pereutaneous coronary intervention[J]. Aeta Radiol,2010,51 (6) : 641-648.
  • 5Elkayam U,Akhter MW, Liu M, et al. Assessment of renal hemodynamic effects of nesiritide in patients with heart failure using intravascular Doppler and quantitative angiography[J]. JACC Cardiovasc Imaging,2008,1 (6) :765-771.
  • 6Chen HH,Cataliotti A,Schirger J A,et al. Local renal delivery of a na- triuretic peptide a renal-enhancing strategy for B-type natriuretic pep- tide in overt experimental heart failure [J]. J Am Coil Cardiol,2009,53 (15) : 1302-1308.

二级参考文献14

  • 1DE CASTRO F D, CHAVES P C, LEITE-MOREIRA A F. Cardiorenal syndrome and its pathophysiotogieal implications [J]. RevPort Cardiol, 2010, 29(10): 1535-1554.
  • 2KEATING G M, GOA K L. Nesiritide: a review of its use in aeute deeompensated heart failure[J]. Drugs, 2003, 63 (1) : 47-70.
  • 3OWAN T E, CHEN H H, FRANTZ R P, et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction[J]. J Card Fail, 2008, 14(4): 267-275.
  • 4MILLER W L, KURIEN S, WARFIELD K T, et al. Lack of association between worsening renal function and mortality in heart failure patients treated with nesiritide[J]. Int J Cardiol, 2008, 126(2): 234-239.
  • 5ZHANG J, FU X, JUA X, et al. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention[J]. Acta Radiol, 2010, 51(6): 641-648.
  • 6ELKAYAM U, AKHTER M W, LIU M, et al. Assessment of renal hemodynamic effects of nesiritide in patients with heart failure using intravascular Doppler and quantitative angiography[J]. JACC Cardiovasc Imaging, 2008, 1 (6) : 765-771.
  • 7CHEN H H, CATALIOTTI A, SCHIRGER J A, et al. Local renal delivery of a natriuretie peptide a renal-enhancing strategy for B-type natriuretie peptide in overt experimental heart failure [ J ]. J Am Coll Cardiol, 2009, 53 ( 15 ) 1302-1308.
  • 8BRUNNER-LA ROCCA H P, KAYE D M, WOODS R L, et al. Effects ozf intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects [J]. J Am Coll Cardiol, 2001, 37(5): 1221-1227.
  • 9JENSEN K T, CARSTENS J, PEDERSEN E B. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans[J]. Am J Physiol, 1998, 274(1 Pt 2) F63-F72.
  • 10SACKNER-BERNSTEIN J D, SKOPICKI H A, AARONSON K D. Risk of worsening renal function with nesiritide in patients with acutely deeompensated heart failure [J]. Circulation, 2005, 111(12): 1487-1491.

共引文献20

同被引文献44

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部